CSPC Pharmaceutical Group (01093) presented Phase I data for SYS6002 monotherapy in advanced cervical cancer at the IGCS 2026 Annual Meeting. The multicenter trial enrolled 82 patients across two regimens (2.4 mg/kg Q2W and 3.6 mg/kg Q3W), with a median follow-up of 16.1 months. Safety was manageable, with predominantly Grade 1-2 treatment-related adverse events (TRAEs), a 2.4% incidence of interstitial lung disease, and no treatment-related deaths or severe ocular events. Confirmed objective response rates (ORRs) were 35.9% and 28.6%, respectively. Median duration of response was 8.2 and 10.3 months, median progression-free survival (PFS) was 4.1 and 4.3 months, and median overall survival (OS) was 15.1 and 11.5 months. CSPC has advanced the 2.4 mg/kg Q2W regimen to Phase III testing (NCT07230626) in patients with immunotherapy-refractory advanced cervical cancer.

On October 8, 2026, Optoseeker Biotechnology (Shenzhen) Co., Ltd. (hereinafter "OptoSeeker") announced the close of a Pre-A funding round of more than RMB 50 million. The round was led by Shenzhen Capital Group, with Guangdong Traditional Chinese Medicine Health Equity Investment Fund Partnership Enterprise (Limited Partnership), Nanshan SEI Investment, and LINGYI CAPITAL participating. The proceeds will be used mainly for core product R&D and engineering, validation of key application scenarios, and further exploration of an AI-driven technical service model. OptoSeeker will continue to deepen its product and application footprint in antibody discovery, cell line development, and cell and gene therapy, and explore new technical service capabilities built around single-cell functional data.

Hong Kong's healthcare IPO market weakened sharply in 2026 as listing premiums faded and investor sentiment cooled. In Q3, only two healthcare companies went public, both suffering first-day losses. Highly anticipated listings such as MEDCAPTAIN and Beijing TRT Healthcare also saw steep post-listing declines, with some new listings falling over 60%. The downturn reflects tighter primary-market risk appetite, weaker secondary-market confidence, and reduced tolerance for valuations based on early-stage narratives. IPO activity has consequently slowed, with more companies delaying or abandoning plans. A key factor is the crowded approval pipeline: 87 companies remained in the queue as of September 21, prolonging review cycles and discouraging new applications. The market is entering a phase of more rational restructuring.

Shenzhen Shenyi Technology, founded in May 2025, focuses on "AI + brain science," productizing brain-computer interface (BCI) technology for real-world use. It closed an angel round of over RMB 10 million led by Leaguer Venture Capital. Founder Gu Xiangkun advocates "ask about the scenario first, then choose the technology": as sleep and emotion management need long-term intervention and surgery sees low acceptance, Shenyi chose a non-invasive route to reach more people. Its two-way "acquisition–understanding–intervention" loop captures EEG signals via self-developed modules, analyzes brain states and disease features with AI algorithms, then applies neuromodulation, completing a "perception–understanding–intervention–feedback" cycle. Shenyi is exploring productization in sleep improvement, depression treatment, and deep-brain modulation, addressing the industry's fragmented single-point technologies and scaling brain health technology systematically.

GensKey’s self-developed mNGS kit has received a Class III medical device registration certificate from China’s National Medical Products Administration (NMPA), marking China’s first Class III registration for pathogen metagenomic testing and the first mNGS infectious pathogen diagnostic kit approved by a national regulator worldwide. The U.S. FDA has yet to approve any mNGS diagnostic kit, while the EU has not completed approval of any broad-spectrum infectious pathogen mNGS sequencing kit. China’s lead reflects strong clinical demand and rapid technological iteration. With mNGS and tNGS still at low penetration but high growth, clinical needs are accelerating standardization, regulatory approval and reimbursement. As a key tool for severe and complex infections, mNGS has historically relied on centralized laboratories with limited standardization. The new Class III approval could reshape the market and unlock a billion-yuan incremental opportunity.

Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced on October 8, 2026, that it has received a Drug Registration Certificate from China's National Medical Products Administration for its sacubitril/valsartan sodium tablets. The company had initially submitted its marketing authorization application for the drug in April 2025.

In September, China's pharmaceutical sector witnessed a surge of innovative approvals from the NMPA across multiple therapeutic areas, including hematologic cancers, mental health, pediatric infections, and cardiovascular diseases. Key breakthroughs include new treatments for multiple myeloma, domestic TCM innovations for depression, and monoclonal antibodies for RSV prevention in infants. Alongside imported and domestic drugs, advanced medical devices for myopia correction, rare disease screening, and intracranial stenosis also received clearance. This wave of approvals underscores China's diversified medical innovation landscape, significantly enhancing clinical treatment capabilities and accelerating patient access to cutting-edge therapies nationwide.

Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA, 02659) shares jumped over 15% in early Hong Kong trading as the biotech firm reported steady progress across its lead programs. Key catalysts include the NDA acceptance for KJ103, a kidney transplant desensitization therapy, following a successful Phase 3 readout, and the regulatory approval of KJ017 in China in March 2026. With over 60 partners now utilizing KJ017, the company is advancing its commercial roadmap while demonstrating strong clinical momentum across its pipeline.

On October 8, 2026, Beijing-based Beizhuo Medical announced the close of a nearly RMB 100 million Pre-A round. The round was co-led by YuanMing Capital and ZGC Capital, with Guangzhou Sairuibo Medical Technology and other industrial investors participating, and Investarget and Yixin Capital serving as joint financial advisors. The proceeds will be used for core technology iteration, clinical pipeline advancement, medical device registration, and overseas expansion, accelerating the commercialization of China's original non-invasive brain-computer technology and moving neurological care from experience-based "one-size-fits-all" treatment toward a new era of individualized precision therapy.

On October 8, 2026, HongShan announced that it had completed, at the end of September, a controlling acquisition of Jiangyin PeierTech Co., Ltd. ("PeierTech") and its wholly owned subsidiaries. Founded in 2002 and headquartered in Jiangyin, Jiangsu, PeierTech focuses on medical nitinol materials, precision nitinol components, and precision assembly, and is one of Asia's few leading suppliers with full-chain, one-stop capabilities. Following the transaction, HongShan holds about 80% of PeierTech's equity, while the existing management team retains the remaining stake and will continue to run day-to-day operations. HongShan will also grant the core management team a market-based equity incentive plan to support the company's continued business growth and accelerate its globalization.

Physical AI is attracting capital in AI-driven drug discovery. Transfyr, founded in August 2026, raised $25 million in seed funding; Shuye Technology completed a Pre-A round in September to develop self-driving laboratories; Jindu Life Sciences raised nearly RMB 100 million in Series A funding in June; and Medra raised $52 million in Series A funding in late 2025, bringing total funding to $63 million. These startups integrate real-world perception, equipment control, and automated decision-making to develop physical AI scientists and transform life science research. Despite ongoing debate over the definition of Physical AI, investors are backing large-scale early-stage projects, accelerating the integration of AI for Science (AI4S) with physical experiments to overcome traditional limitations in AI-driven drug discovery. No specific investors or financial advisors were disclosed.

Hong Kong's healthcare IPO market weakened sharply in 2026 as listing premiums faded and investor sentiment cooled. In Q3, only two healthcare companies went public, both suffering first-day losses. Highly anticipated listings such as MEDCAPTAIN and Beijing TRT Healthcare also saw steep post-listing declines, with some new listings falling over 60%. The downturn reflects tighter primary-market risk appetite, weaker secondary-market confidence, and reduced tolerance for valuations based on early-stage narratives. IPO activity has consequently slowed, with more companies delaying or abandoning plans. A key factor is the crowded approval pipeline: 87 companies remained in the queue as of September 21, prolonging review cycles and discouraging new applications. The market is entering a phase of more rational restructuring.

On September 29, 2026, Shanghai Pharmaceuticals Holding Co., Ltd. (SPH) announced plans to sell its entire stake in ZIL, an overseas asset held for a decade, to Primavera Capital at an enterprise value of $397 million. The deal is expected to generate approximately RMB 1.336 billion in profit. Following the transfer of Xinte Dong'an Pharmacy, it marks another step in SPH's asset optimization and focus on its core pharmaceutical business. SPH acquired Australian company Vitaco in 2016 to integrate overseas brands with Chinese distribution channels, but expected synergies failed to materialize amid regulatory and cross-border policy changes. As Vitaco shifted toward sports nutrition, its relevance to SPH's core business weakened. The exit concludes SPH's decade-long overseas investment and reflects the broader shift among Chinese pharmaceutical SOEs toward value-focused operations and core capabilities.

On September 18, 2026, the NMPA approved Xinhuanghe Pharma's Budesonide and Formoterol Fumarate Powder for Inhalation (II) for marketing. As China's first approved generic of the product, the approval breaks a foreign monopoly of more than two decades and marks a domestic drugmaker's breakthrough at the "Everest" of dry powder inhalation. Xinhuanghe Pharma's predecessor traces back to Jiufu Pharmaceutical, founded in 1923, which was later folded into Shanghai Pharmaceuticals (SPH) and acquired and renamed by Chenpon in 2014. Amid an industry transition, Chairman Peng Zhaohua chose dry powder inhalation — a technically demanding drug-device combination — over low-cost generics and the hot biologics track. After prolonged investment and R&D breakthroughs across API, formulation, and device, the company has revived a veteran drugmaker and brought patients a high-value domestic alternative.

South Korea’s “cadaver skin injection” Re2O, derived from donated human skin tissue, has sparked ethical and safety concerns in China, bringing extracellular matrix (ECM) into focus. After decellularization, ECM retains biological activity and is widely used in tissue repair. Related medical devices are approved in China, but facial wrinkle reduction is prohibited. Identified as an aging biomarker in 2025, ECM is gaining new applications in medical aesthetics amid advances in microparticulate technology. China’s ECM industry is growing rapidly, with firms such as Shengzhi Runhe and Medgen Life Sciences raising multiple financing rounds and expanding from R&D to mass production. Major medical aesthetics and pharmaceutical companies are also investing in the field, driving ECM toward commercialization.

Dr. Friedemann Janus, Senior Vice President of Bayer's Pharmaceuticals Division, said China's innovative drugs are embedding deeply into the global system, with about a third of drugs in development originating from China. Multinational pharma's China strategy has shifted from license-in of mature pipeline assets to early engagement with biotech teams to grasp their innovation logic. Bayer, which sees China as a key source of high-quality innovation, has built a network linking startups with global capital and R&D experts via Co.Lab sites in Shanghai and Beijing, a venture capital alliance, and global roadshows during 2024–2025. Janus believes China's pharma industry has moved past "Me-too" and "Fast-Follow" toward "Best-in-Class." The core issue now is how multinational pharma can embed even earlier in China's innovation ecosystem and drive local innovation into global R&D, business development, and commercialization — a fundamental elevation of China's global pharma position.

Innovative drug R&D insurance is an emerging track in China's pharma industry, sharing drugmakers' R&D failure risk via financial tools. PICC P&C, with Taiping P&C and Sunshine P&C, recently issued the first life-science R&D insurance policy in Beijing — a breakthrough for China. It distinguishes clinical liability insurance (third-party liability) from R&D loss insurance (drugmakers' own losses). Overseas, Clinical Trial Funding Insurance (CTFI) is key: it reimburses incurred costs when a trial misses its primary endpoints, shifting risk from drugmakers to insurers. MCI (Medical & Commercial International) and peers underwrite Phase I, Phase II, and select small Phase III trials with USD 3–35 million budgets, covering small molecules and antibodies but not gene therapies. This gives domestic drugmakers a risk-hedging tool, signaling deeper integration of tech finance and biomedicine.

On September 21, 2026, Beijing Port became the first in China to fully digitize customs clearance for imported drugs, issuing the nation’s first electronic “Import Drug Customs Clearance Slip.” The reform replaces paper-based counter processing with an online workflow covering application, review, electronic seal generation, and self-printing. QR codes enable real-time verification. Processing time has been reduced to minutes, with documents issued within seconds, cutting labor and time costs. The reform improves cross-border trade efficiency, accelerates imports of urgently needed rare disease drugs and key APIs, and supports the biopharmaceutical industry. Combined with Beijing Port’s “Green First” inspection service, it further expedites product market entry and enhances efficiency across the pharmaceutical import supply chain.

A wave of 'pharma second-gens'—mostly in their early 30s with elite global educations and diverse professional backgrounds—are stepping into leadership roles at multi-billion-dollar Chinese pharmaceutical companies. From Joincare’s Zhu Linlin and CSPC’s Cai Lei to MicroPort’s Brian Chang and Hualan Biological Bacterin’s An Wenjue, these heirs are driving strategic pivots toward innovation, internationalization, and capital-driven growth. Their rise coincides with industry-wide shifts away from generic drugs amid pricing pressures, as they leverage expertise in R&D, M&A, and global business development to navigate a new era of biopharma competition.

As the first Chinese company to obtain a Class III medical device registration certificate for AI in IVD, Aimagine Care is using its self-developed large language model and rapid fine-tuning capabilities to expand beyond blood testing equipment. It aims to build an AI-driven laboratory ecosystem covering testing, research, education, operations, and regulatory compliance. The path to full intelligence comprises four stages: foundational, advanced, derivative, and regulatory. The foundational stage covers automated workflows, result interpretation, and risk alerts, while the advanced stage focuses on intelligent testing pathways and project coordination. However, even highly automated biochemical and immunological lines have yet to achieve end-to-end automation, underscoring the long-term challenge of advancing from process automation to comprehensive laboratory intelligence.

In the first three quarters of 2026, Medtronic invested approximately $2.7 billion in intensive M&A activities. This included leading a $100 million Series D financing round for China-based Pulnovo Medical. Additionally, Medtronic made strategic investments of approximately $700 million in China's Cornerstone Robotics and Israel's Pi-Cardia; acquired three companies, including CathWorks and Scientia Vascular; and invested in Beluga Medical and CARDIOACC. Although the specific financial advisors were not explicitly mentioned in the text, PwC provided relevant data support. Leveraging its strong cash flow, Medtronic aims to address gaps in cardiology and neuroscience through strategic acquisitions, rapidly acquiring high-growth, near-commercialization innovative technologies to synergize with existing businesses and drive growth.

In late September, two global oncology BD deals worth about $2 billion each highlighted the value of Chinese innovative drugs. MSD is acquiring SciBrunch's preclinical oral KRAS G12D inhibitor SPR2015 for up to $2.13 billion to strengthen its solid tumor pipeline. AstraZeneca is investing $2 billion in Summit Therapeutics to advance combination therapies involving Akeso's ivonescimab and CLDN18.2 ADC, while expanding collaboration on multiple ADCs. Despite similar deal sizes and Chinese origins, the transactions reflect different strategies: MSD is using a preclinical small molecule to fill pipeline gaps, while AstraZeneca is leveraging a mature bispecific antibody to explore combination therapies. The deals highlight diverse asset stages, deal structures, and strategic approaches in global oncology BD, as well as the growing global value of Chinese biopharmaceutical innovation.

On September 28, 2026, Shanghai SciBrunch and MSD announced a global exclusive licensing agreement for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor. Under the agreement, SciBrunch grants MSD exclusive worldwide rights to develop, manufacture, and commercialize SPR2015. The deal includes a $400 million upfront payment and milestone payments, with a potential total value of up to $2.13 billion. SPR2015 is a potent and selective molecular glue inhibitor targeting KRAS G12D, the most common KRAS mutation in human tumors. Preclinical studies showed significant antitumor activity across multiple models while maintaining favorable selectivity for wild-type KRAS. The collaboration validates SciBrunch’s R&D capabilities in RAS-targeted therapies and strengthens MSD’s precision medicine pipeline, with potential applications in pancreatic, colorectal, and lung cancers.

Dr. Friedemann Janus, Senior Vice President of Bayer's Pharmaceuticals Division, said China's innovative drugs are embedding deeply into the global system, with about a third of drugs in development originating from China. Multinational pharma's China strategy has shifted from license-in of mature pipeline assets to early engagement with biotech teams to grasp their innovation logic. Bayer, which sees China as a key source of high-quality innovation, has built a network linking startups with global capital and R&D experts via Co.Lab sites in Shanghai and Beijing, a venture capital alliance, and global roadshows during 2024–2025. Janus believes China's pharma industry has moved past "Me-too" and "Fast-Follow" toward "Best-in-Class." The core issue now is how multinational pharma can embed even earlier in China's innovation ecosystem and drive local innovation into global R&D, business development, and commercialization — a fundamental elevation of China's global pharma position.

China’s Center for Drug Evaluation (CDE) has nominated two MASH drug candidates for breakthrough therapy designation: Zhongsheng Pharmaceutical’s ZSP1601 tablets and GSK’s injectable Efimosfermin alfa. ZSP1601, a first-in-class pan-phosphodiesterase (PDE) inhibitor, has entered Phase III trials after showing significant pathological improvement in Phase IIb. At 48 weeks, response rates were 64.9% (100 mg) and 57.6% (50 mg), versus 32.5% for placebo. The drug demonstrated anti-fibrotic effects, reduced liver fat, and improved liver enzymes, with a favorable safety profile. Efimosfermin alfa, a long-acting FGF21 analog administered monthly by subcutaneous injection, is designed to reduce liver fat, improve inflammation, and reverse fibrosis. GSK acquired rights to the drug for up to USD 2 billion and has registered the Phase III ZENITH-2 trial in China following positive Phase II results showing significant histological response in patients with F2/F3 MASH.

On September 22, Suzhou BoomRay announced an exclusive global licensing agreement with Novartis for one of its preclinical radioligand therapy (RLT) assets. BoomRay is eligible to receive up to USD 900 million (approximately RMB 6 billion), including upfront and milestone payments, plus sales royalties. This marks Novartis’s second licensing of an early-stage RLT asset from China this year, following its January acquisition of assets from Hunan PepLib. Despite strong RLT sales, including over USD 1.9 billion in 2025 revenue from Pluvicto, Novartis continues to seek external collaborations to expand its next-generation pipeline targeting novel antigens, ligands, and radionuclides. Founded in 2018, BoomRay has developed an RLT platform covering multiple targets. The deal highlights the global licensing potential of Chinese biotech RLT assets and the growing focus of multinational pharmaceutical companies on early-stage RLT opportunities.

At CCOS 2026, Zhang Jian, vice president of Alcon China, said innovation value must be reflected in responding to real clinical needs and benefiting patients. As China's ophthalmic demands shift from basic "blindness treatment" toward high-definition, personalized, all-scenario visual quality, competition now extends to clinical application capability, professional education, and local innovation. Alcon is redefining its value in China by deepening the integration of global innovation with local clinical practice. It showcased products including the Clareon intraocular lens, the Constellation system, and the ARGOS biometer, and is advancing the rollout of Unity VCS — marking a shift from single devices to systematic clinical solutions, and aiming to complete innovation's "last mile" through continuous clinical validation to genuinely improve patient outcomes.

On September 3, 2026, HUTCHMED announced a worldwide license agreement with GSK for HMPL-A830, its first-in-class KRAS-EGFR dual-targeting antibody-targeted conjugate (ATTC), granting GSK exclusive development and commercialization rights outside Greater China. The drug pairs an anti-EGFR antibody with a KRAS inhibitor payload to dually block signaling pathways, aiming to improve efficacy and tolerability in KRAS-mutant colorectal, pancreatic, and lung cancers. HUTCHMED will receive a USD 110 million upfront payment plus up to USD 1.185 billion in milestones and royalties, retaining Greater China rights; GSK also secured priority negotiation rights for another early-stage ATTC. A global Phase I study led by HUTCHMED is expected in H2 2026, with GSK leading overseas development and commercialization — a milestone for precision oncology addressing unmet need for safe, durable regimens.

Hansoh Pharmaceutical Group has submitted a China marketing application for risvutatug rezetecan (HS-20093), a fully human B7-H3 ADC with a topoisomerase inhibitor payload, for platinum-refractory small cell lung cancer (SCLC). The filing is supported by positive Phase III ARTEMIS-008 results announced in July 2026, which met its primary overall survival endpoint and significantly improved survival versus topotecan, with consistent progression-free survival benefits. Safety remained consistent with prior studies. This is the first positive Phase III result showing a B7-H3 ADC can significantly improve overall survival. In December 2023, Hansoh granted GSK exclusive rights to develop and commercialize the drug outside Greater China, where GSK is conducting Phase III trials. As SCLC accounts for about 15% of lung cancers and has limited second-line options, HS-20093 could address a significant unmet medical need.

On September 1, 2026, Medtronic announced a strategic partnership with Chinese surgical robotics company Cornerstone Robotics, investing approximately $700 million for distribution rights of the Sentire® robotic-assisted laparoscopic surgery system outside the U.S. The Sentire platform features fully in-house developed core technologies, including the world’s first 5mm wristed instruments, 8mm 4K 3D fluorescence imaging, and proprietary force-feedback and direct-drive control systems. This investment complements Medtronic’s existing Hugo™ system, creating a dual-platform strategy that addresses diverse surgical specialties and economic markets. With regulatory approvals already secured in China (NMPA), Europe (CE), and Singapore (HSA), the deal accelerates Medtronic’s global surgical robotics rollout amid intensifying competition and strategic pressure on its traditional surgical device business.